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Abstract
Background: Cancer has remarkable complexity at the molecular level, with multiple genes, proteins, pathways
and regulatory interconnections being affected. We introduce a systems biology approach to study cancer that
formally integrates the available genetic, transcriptomic, epigenetic and molecular knowledge on cancer biology
and, as a proof of concept, we apply it to colorectal cancer.
Results: We first classified all the genes in the human genome into cancer-associated and non-cancer-associated
genes based on extensive literature mining. We then selected a set of functional attributes proven to be highly
relevant to cancer biology that includes protein kinases, secreted proteins, transcription factors, post-translational
modifications of proteins, DNA methylation and tissue specificity. These cancer-associated genes were used to
extract ‘common cancer fingerprints’ through these molecular attributes, and a Boolean logic was implemented in
such a way that both the expression data and functional attributes could be rationally integrated, allowing for the
generation of a guilt-by-association algorithm to identify novel cancer-associated genes. Finally, these candidate
genes are interlaced with the known cancer-related genes in a network analysis aimed at identifying highly
conserved gene interactions that impact cancer outcome. We demonstrate the effectiveness of this approach using
colorectal cancer as a test case and identify several novel candidate genes that are classified according to their
functional attributes. These genes include the following: 1) secreted proteins as potential biomarkers for the early
detection of colorectal cancer (FXYD1, GUCA2B, REG3A); 2) kinases as potential drug candidates to prevent tumor
growth (CDC42BPB, EPHB3, TRPM6); and 3) potential oncogenic transcription factors (CDK8, MEF2C, ZIC2).
Conclusion: We argue that this is a holistic approach that faithfully mimics cancer characteristics, efficiently
predicts novel cancer-associated genes and has universal applicability to the study and advancement of cancer
research.
Background
Cancer is a complex genetic disease that exhibits
remarkable complexity at the molecular level with mul-
tiple genes, proteins and pathways and regulatory inter-
connections being affected. Treating cancer is equally
complex and depends on a number of factors, including
environmental factors, early detection, chemotherapy
and surgery. Cancer is being recognized as a systems
biology disease [1,2], as illustrated by multiple studies
that include molecular data integration and network and
pathway analyses in a genome-wide fashion. Such stu-
dies have advanced cancer research by providing a glo-
bal view of cancer biology as molecular circuitry rather
than the dysregulation of a single gene or pathway. For
instance, reverse-engineering of gene networks derived
from expression profiles was used to study prostate can-
cer [3], from which the androgen-receptor (AR)
emerged as the top candidate marker to detect the
aggressiveness of prostate cancers. Similarly, sub-
networks were proposed as potential markers rather
than individual genes to distinguish metastatic from
non-metastatic tumors in a breast cancer study [4]. The
authors in this study argue that sub-network markers
* Correspondence: Tony.Reverter-Gomez@csiro.au
Computational and Systems Biology, Commonwealth Scientific and Industrial
Research Organisation (CSIRO), Division of Livestock Industries, Queensland
Bioscience Precinct, 306 Carmody Road, St. Lucia, Brisbane, Queensland 4067,
Australia
Nagaraj and Reverter BMC Systems Biology 2011, 5:35
http://www.biomedcentral.com/1752-0509/5/35
© 2011 Nagaraj and Reverter; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
are more reproducible than individual marker genes
selected without network information and that they
achieve higher accuracy in the classification of meta-
static versus non-metastatic tumor signaling. Using gen-
ome-wide dysregulated interaction data in B-cell
lymphomas, novel oncogenes have been predicted
in-silico [5]. Finally, taking a signaling-pathway approach,
a map of a human cancer signaling network was built [6]
by integrating cancer signaling pathways with cancer-
associated, genetically and epigenetically altered genes.
Gene expression profiling has been widely used to
investigate the molecular circuitry of cancer. In particu-
lar, DNA microarrays have been used in almost all of
the main cancers and promise to change the way cancer
is diagnosed, classified and treated [1]. However, expres-
sion analyses often result in hundreds of outliers, or dif-
ferentially expressed genes between normal and cancer
cells or across time points [2]. Owing to the large num-
ber of candidate genes, several different hypotheses can
be generated to explain the variation in the expression
patterns for a given study. In addition, the preferential
expressions of some tissue-specific genes present addi-
tional challenges in expression data analyses. Neverthe-
less, recent systems approaches have attempted to
prioritize differentially expressed genes by overlaying
expression data with molecular data, such as interaction
data [3], metabolic data [4] and phenotypic data [5].
Human malignancies are not just confined to genes
and gene products, but also include epigenetic modifica-
tions such as DNA methylation and chromosomal aber-
rations. However, in order to effectively capture the
properties that emerge in a complex disease, we need
analytical methods that provide a robust framework to
formally integrate prior knowledge of the biological
attributes with the experimental data. The simplest
heuristic will search for novel genes with a profile, in
terms of differential expression and/or network connec-
tivity, similar to those for which an association to dis-
ease has been well established (see, for instance, the
approaches of [7,8]).
Boolean logic has been found to be optimal for such
tasks. Within the context of cancer, Mukherjee and
Speed [9] show how a series of biological attributes
including ligands, receptors and cytosolic proteins, can
be included in the network inference. More recently,
Mukherjee and co-workers [10] introduced an approach
based on sparse Boolean functions and applied it to the
responsiveness of breast cancer cell lines to an anti-
cancer agent. In addition, large scale literature-based
Boolean models have been used to study apoptosis path-
ways as well as pathways connected with them.
In this study, we propose a systems biology approach
to predict disease-associated genes that are either not
previously reported (novel) or poorly characterized and
using colorectal cancer as a case study. To achieve this
goal, we first implemented a Boolean logic schema
derived from cancer-associated genes and developed a
guilt-by-association (GBA) algorithm, which is subse-
quently applied in a genome-wide fashion. Although
gene expression data are central to this approach, other
biologically relevant functional attributes, such as tissue
specificity, are treated as equally important in the Boo-
lean logic informing the GBA algorithm. Finally, novel
cancer-associated genes are interlaced with the known
cancer-related genes in a weighted network circuitry
aimed at identifying highly conserved gene interactions
that impact cancer outcome.
Results and Discussion
Overview of the systems biology approach
Figure 1 shows the schema of the proposed analytical
approach. The first phase deals with the analysis of gene
expression data to obtain a list of differentially expressed
and condition specific genes. Conceptually, differentially
expression differs from condition specificity in that the
former requires the postulation of a contrast of interest
while the latter enriches for genes that are preferentially
expressed in one of the (potentially many) experimental
conditions being considered. Nevertheless, the expecta-
tion is for a substantial overlap in the genes identified
between either criterion. In the second phase, public
databases are mined to compile a list of cancer-asso-
ciated genes, non cancer-associated genes and functional
attributes that are of relevance in the context of cancer.
We considered a total of six functional attributes as fol-
lows: tissue specificity (TS), transcription factors (TF),
post-translational modifications (PTM), kinases (KIN),
secreted proteins (SEC) and CpG island methylation
(MET)(see Additional File 1 for rationale behind choos-
ing these attributes). Table 1 summarizes the general
characteristics of the functional attributes with a few
prototypic examples of representative genes. Additional
File 2 provides the list of 749 cancer-associated genes
that we compiled within each attribute. These features
were selected based also on the fact that there is a
strong functional interconnection among them and
therefore we see the overlapping of these genes across
attributes.
The resulting set of variables (differentially expression,
condition specificity, and the six functional attributed)
are each binarized and used in a Boolean logic frame-
work. The Boolean logic is then applied to cancer-
associated genes to develop a GBA algorithm. When
applied to non cancer-associated genes, the GBA algo-
rithm preferentially ranks those genes whose behavior
across all variables most mimics that of cancer-asso-
ciated genes. Finally, in order to gain a global under-
standing of the novel candidate genes, we generate a
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series of gene co-expression networks. The resulting
networks are surveyed with a focus on the interacting
partners of candidate genes and within the context of
the original functional attributes.
Differentially expressed and condition specific genes
We explored three measures of differential expression
(DE1 = Carcinoma - Normal; DE2 = Carcinoma - Ade-
noma; and DE3 = Carcinoma - Inflammation) and iden-
tified 444, 658 and 179 differentially expressed genes for
DE1, DE2, and DE3, respectively. We observed several
overlaps among the three differentially expressed gene
categories, and 15 genes were found to be differentially
expressed in all three categories (Figure 2). Among
them, we highlight CLCA4, CRNDE, DEFA5, DUOXA2,
GCG, KLK10, and UGT2A3. In particular, CRNDE (col-
orectal neoplasia differentially expressed) was the most
differentially expressed (up-regulated) gene with a 16-
fold change in expression. CRNDE gene is localized to
chromosome 16 (16q12.2) and is poorly characterized
with no functional information on its role in colorectal
cancer except its differential expression from the EST
data (UniGene Id: 167645). Another differentially
expressed gene KLK10 is a member of the kallikrein
gene family which is well documented biomarker for the
detection of colon, ovarian and pancreatic cancers
[8,11].
In addition, we identified 83, 61, 23, and 48 condition
specific genes for Normal, Adenoma, Carcinoma and
Inflammation, respectively. Among these genes, 23 were
found to be specific to carcinoma (CS3) (see Additional
File 1 Table S1). Notably, CCDC3, EREG, IL6, PAPPA,
SERPINE1, TFPI2 and THBS2 are a few examples of the
condition specific genes that appeared as top candidates.
Figure 1 The schema for the identification of novel genes associated with complex diseases. The expression profiles from the cancer data
are analyzed to predict differentially expressed and condition-specific genes. The functional attributes over-represented in cancer are selected
and representative datasets from public resources mined. The common cancer fingerprints from cancer-associated genes are processed through
Boolean logic to develop a guilt-by-association classifier which, applied to non-cancer-associated genes, predicts novel candidate cancer-
associated genes. Finally, novel candidate genes are further analyzed using network theory approaches.
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In particular, CCDC3 (coiled-coil domain containing
3) and TFPI2 (tissue factor pathway inhibitor 2) genes
were the most carcinoma-specific genes.TFPI2 has been
proposed to be a tumor suppressor gene as it’s fre-
quently methylated in colorectal cancer [7]. The CCDC3
encoded protein is predicted to be localized to extracel-
lular matrix [12] with no previous association with col-
orectal cancer. Higher IL-6 levels might be prognostic
indicator in colorectal cancer as they are associated with
increasing tumor stages and tumor size, with metastasis
and decreased survival [13].
Expression-profiling analyses often result in hundreds
of candidate genes. The challenge is exacerbated when
the expression data are gathered at different time points
or in multiple conditions, as in the current study with a
number of differentially expressed and condition specific
genes. Nevertheless, it is a common practice to stop the
in-silico expression analysis with the list of outliers and
select one or more genes for experimental characteriza-
tion based on the underlying biology. Often, expression
data analyses are accompanied by downstream bioinfor-
matics investigations such as Gene Ontology (GO)
Table 1 Overview of the genetic, epigenetic and molecular information used in this study
Functional
Attribute
Role in Cancer Potential application Examples Data source Reference
Cancer
associated
genes
Genes with at least 2 mutations in
causally implicated in cancer.
Includes oncogenes, tumor
suppressor genes
Potential drug targets and
diagnostic or prognostic
markers
Oncogenes: BCL2, c-Jun, ERG,
ERBB2, RAS, c-MYC, c-SRC
Tumor Suppressor Genes:
RB1, P53, APC, BRCA-1,
BRCA-2
http://www.
sanger.ac.uk/
genetics/CGP/
Census/
http://hprd.org/
Reviews:
(Futreal et al,
2004; Hahn et al,
2002; Mitelman,
2000; Vogelstein
et al, 2004)
NA
Non-cancer
associated
genes
There is no previous report of any
causal mutation.
If cancer association is
established, these genes are
either potential drug
targets and diagnostic or
prognostic markers
AMN, B3GNTL1, CDC42BPB
S100A9, TRPM6, VNN1, ZIC2
NCBI - Human
Genome
http://www.ncbi.
nlm.nih.gov/
projects/genome/
guide/human/
NA
Kinases More than 30% of cancer related
genes are kinases and the most
common domain that is encoded
by cancer genes is the protein
kinase domain
Drug targets through
inhibitors
c-Src, c-Abl, RAS, mitogen activated
protein (MAP) kinase,
phosphotidylinositol-3-kinase
(PI3K), AKT, and the epidermal
growth factor receptor (EGFR)
Human Kinome
Consortium
http://kinase.com/
human/kinome/
[15]
[17,51]
Excretory -
Secretory
proteins
Malignant tumors secrete
increased levels of ES proteins
non-invasive diagnostic or
prognostic markers for early
detection
alpha-fetoprotein, CD44, kallikrein
6, kallikrein 10, MIC-1
Secreted Protein
Database (SPD)
http://spd.cbi.pku.
edu.cn/
[52,53]
[54]
[55]
Transcription
factors
Overactivity of TFs at different
stages of cancer is well
documented and novel treatment
strategies have been suggested
for targeted inhibition of
oncogenic TFs
Alternative therapeutic
strategy, potential drug
targets
C-MYB, NF-kappaB, AP-1, STAT and
ETS transcription factors
Genomatix
http://www.
genomatix.de/
[15,56]
[57]
[58]
DNA
Methylation
Methylation patterns are altered in
cancer cells as shown in
hypomethylation of oncogenes
and hypermethylation of tumor
suppressor resulting in gene
silencing or gene inactivation
CpG island methylation
could be used as a
biomarker of malignant
cells
hMLH1, BRCA1, MGMT, p16(INK4a),
p14(ARF), p15(INK4b, DAPK, APAF-1
Human Colon
Methylome from
[29]
[27,59]
[28]
[60,61]
Post-
translational
modifications
Key proteins driving oncogenesis,
Can undergo PTM Although
Phosphoryltion is partially covered
in kinases section, other PTMs
such as glycosylation and
ubiquitination reported to play a
role in malignancies, are included
separate functional gene
attributes.
BRCA1, EGFR, c-Src, c-Abl, RAS, TP53 HPRD http://hprd.
org/
[18]
Burger
and Seth,
2004)
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enrichment, pathway mapping and network reconstruc-
tion. It is also believed that expression data are not suf-
ficient to accurately reconstruct biological networks [14]
and that the incorporation of additional biological data
is required to constrain the number of plausible hypoth-
eses. We approached this challenge by first identifying
the most relevant functional attributes that has been
well documented in cancer and then extracting this
information to build a Boolean logic.
Boolean logic to develop a guilt-by-association (GBA)
algorithm
We developed a model to infer a gene’s association to
cancer. The model accommodates biologically motivated
semantics into a Boolean logic schema, but is of a prob-
abilistic nature, allowing it to efficiently and effectively
accommodate noise in biological concepts and data
when ranking candidate genes (see Methods).
We trained the model from data based on the beha-
vior of the cancer-associated genes across 13 binarized
Boolean variables: the three measures of differential
expression (whether or not a gene was differentially
expressed in each of the three contrasts), the four mea-
sures of condition specificity (similarly binarized), and
the six cancer-biology attributes as previously described.
At least one of the 13 variables was assigned to 530 of
the 749 cancer-associated genes. These were used to
construct a probabilistic Boolean truth table (Additional
File 3) with 70 combinations (out of a total of 213 =
8192 possible combinations).
The trained model is efficient in weighing each attri-
bute based on firmly established principles in cancer
biology. For instance, more than 30% of the cancer-
associated genes encode protein kinases [15] and this
information is implemented ‘as is’. In addition the pro-
portion of kinases that undergo a PTM is also stored in
the model and applied to non cancer-associated genes
to capture similar kinases that harbor PTM but are
strongly controlled by differential expression or condi-
tion specific properties in a given expression study.
Furthermore, the flexibility of this method lies in its
ability to simultaneously address different aspects of
cancer. For example, the model predicts novel biomar-
kers by analyzing the genome-wide expression profiles
and exclusively selecting secreted proteins as functional
attributes. This will identify differentially expressed or
condition specific secreted proteins expressed in blood/
serum/urine.
Next, we sought to obtain an overview of the represen-
tation of the 13 binarized Boolean variables across differ-
ent gene classes which might provide additional insights
into features of cancer genes in comparison to other
genes. We selected the following four categories of genes:
i. All the genes included in the analyses (n = 21 892); ii.
The cancer-associated genes (n = 749), iii. The candidate
genes processed by the GBA algorithm (n = 1017); and
iv. The top candidate genes (n = 134, 13.2% of the genes
processed by the GBA). Figure 3 shows the distribution
of the four gene categories across the 13 variables. We
observed enrichment for PTM and secreted proteins in
Figure 2 The classification of differentially expressed genes resulting from the expression data analysis. The top 15 DE genes in all of
the three categories are tabulated with their expression values in normal, adenoma, carcinoma and inflammation.
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both cancer-associated and top candidate genes. For
instance, 40% of cancer-associated genes encoding pro-
tein had a PTM and 98% among the top candidate genes.
Similarly, 8% and 47% of genes encoded for secreted pro-
teins in cancer-associated genes and top candidate genes
respectively. These results lead us to inspect the coverage
for PTM and secreted protein both in cancer-associated
genes as well as other genes as they contributed signifi-
cantly in ranking the candidate genes. Additional File 1
Table S2 Shows exclusive and combined distribution of
secreted proteins and PTM. Using chi-square test of
independence, we examined the association of these two
functional attributes and obtained a significant p-value of
3.713 E-06. This indicates that the association of PTM
and secreted proteins either in combination or individu-
ally in cancer associated genes are significantly different
compared to other genes. Finally, we note that the Boo-
lean logic that gives rise to the GBA algorithm operates
by exploiting the combinatorial nature of the 13 vari-
ables. Although, PTM are over-represented in both can-
cer-associated genes and hence candidate genes, their
inclusion as one among five attributes was necessary as
aberrant activation of signaling pathways drives cancer
progression. For example, phosphorylation [16,17], glyco-
sylation [18] and ubiquitination [19] have been documen-
ted to play key role in cancer progression.
Computational validation of the analytical approach
We designed a two-step approach to ascertain the infer-
ential validity of the proposed GBA. In the first step, we
processed all genes through the Boolean logic using the
previously developed probabilistic truth table. We found
that known cancer genes received an average Boolean
score of 0.219 (range: 0.002 to 0.687), compared to an
average score of 0.081 (range: 0.000 to 0.589) for the
other genes. This indicates that our Boolean logic yields
a score to cancer genes that is on average 2.71-fold
higher than that of candidate genes. This odds ratio was
used as the threshold to be applied for the calibration in
the second step of the validation.
The second step of the validation consisted of a stan-
dard cross-validation schema by which a random 4/5 of
Figure 3 Trends showing the distribution of genes across 13 binarized Boolean variables. Four classes of genes were used for the
comparison; i. all the genes in the human genome (21 892), ii. cancer-associated genes (749), iii. GBA ranked candidate genes candidate genes
(1017) and iv. top candidate genes (134, 13.2%of the GBA ranked candidate genes). PTM and SEC classes are enriched in cancer-associated genes
as well as in candidate genes category.
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the cancer genes comprised the training sample used to
build the GBA to be tested against the remaining 1/5 of
the cancer genes (testing sample). After repeating this
process 1000 times, each with a different 4/5 training/1/
5 testing random samples, we found that a ranked list of
candidate genes comprising the top 13.2% of genes
guarantees a 2.71-fold over-representation of cancer
genes (Figure 4A). We also found that selecting the 50%
most extreme genes, captures 90% of all cancer genes
(Figure 4B).
When the subject is concerned with the identification
of differentially expressed genes after normalising the
data, one can invoke the Gaussian distribution to
produce p-values. Similarly, when the issue is to ascer-
tain enrichment of a particular biological process, one
could invoke the hypergeometric distribution to produce
p-values.
However and quite importantly, no parametric distri-
bution functions were invoked in the development of the
Boolean logic and the subsequent guilt-by-association
algorithm. Instead, the sensitivity of the proposed
approach in terms of its power to detect cancer genes
was explored using a two-step procedures comprised of
first assessing its efficiency when applied to cancer-
associated genes, and then developing a cross-validation
schema to identify the threshold beyond which the power
to detect candidate genes is higher than the one obtained
with known cancer-associated genes.
The emergence of ranked candidate genes from the GBA
algorithm
Table 2 lists the top 20 candidate genes and Additional
File 4 contains the entire ranked list of 134 candidate
genes (or 13.2% of the 1017 genes processed through
the GBA). While a detailed description of the individual
genes is beyond the scope of this study, we focus on
candidates that also figure in the network analysis
section described later, based on their connectivity to
cancer-related genes and their position in the co-
expression network.
Excretory-Secretory proteins as diagnostic or prognostic
biomarkers
ES proteins are particularly relevant in colorectal cancer
because most colorectal cancers develop slowly; begin-
ning as small benign colorectal adenomas that progress
over several years to larger dysplastic lesions that even-
tually become malignant. A total of 178 genes encoding
ES proteins were found using this approach, of which
51 genes were tissue-specific to the colon. 64 entries
had evidence for a PTM and 25 genes showed methyla-
tion in colon cell lines. Among these, we highlight PYY
and GUCA2B. PYY (peptide YY) is a gut hormone
highly expressed in the colon [20] and down regulated
eight-fold in adenomas compared with the normal colon
(Table 2). Its distinct variation in expression levels in
the colon and gut region (gastric mucosa and rectum)
compared with the cancerous colon makes it an impor-
tant candidate gene for detailed biochemical characteri-
zation. As PYY is down regulated in carcinoma, it is
unlikely candidate for early detection as decreased levels
of protein in the cancer would not alter levels in the
peripheral blood. GUCA2B (Uroguanylin) is a physiolo-
gical regulator of intestinal fluid and electrolyte trans-
port, 8-fold down regulated in adenoma, and its
expression is observed in blood and urine [21]. There-
fore, GUCA2B could be exploited as a non-invasive bio-
marker for the early detection of colorectal cancer.
Figure 4 Two-step computational validation approach to
ascertain the inferential validity of the proposed GBA. 4A
shows the ratio of the average Boolean score given to cancer genes
over the average score given to the other genes. Candidate genes
comprising the top 13.2% of genes guarantee a 2.71-fold over-
representation of cancer genes. 4B. Standard cross-validation in
which the proportion of cancer-associated genes are compared to
genes with extreme Boolean scores. By selecting the 50% most
extreme genes captures 90% of all cancer genes.
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Transcription factors as novel oncogenic regulators for the
treatment for colorectal cancer
The altered activity of a few key TFs results in aberrant
expression of their target genes, which can eventually
lead to tumor development. The combination of the
GBA and regulatory impact factor (RIF) analyses yielded
58 TF genes. Thirty-eight of these TFs showed colon-
specific expression, 19 genes had DNA methylation and
6 proteins encoded by TFs had evidence for at least one
PTM (Table 2). Here, we highlight the biological rele-
vance of the top two candidates: SPIB and MEF2C. SPIB
is an adenoma condition-specific down regulated gene.
The DNA-binding ETS domain of SPIB is highly homo-
logous to the ETS domain from the oncoprotein Spi-1/
PU.1 [22] and may be an oncogenic TF awaiting experi-
mental characterization. In addition, SPIB interacts with
the promoter region of the c-JUN oncogene and
MAPK3 gene [23] that are implicated in several cancers,
including ovarian cancer. Similarly, MEF2C has been
proven to play a role in angiogenesis [24], and shown to
be over-expressed in hepatocellular carcinoma [25].
Genes encoding protein kinases
A total of 11 genes encoding protein kinases were identi-
fied of which 2 were tissue-specific and 3 genes were DNA
methylated: EPHB3, NPR1 and TRPM6. EPHB3 is a recep-
tor tyrosine kinase that mediates several developmental
processes [26]. Importantly, EPHB3 interacts with the Fyn
oncogene in vivo, and EPHB3 has a suggested role in
tumor suppression. Other kinases predicted by the GBA
include NPR1, a novel guanylate cyclase that catalyzes the
production of cGMP from GTP and TRPM6, also called
channel kinase 2, which is significantly down regulated in
adenomas.
Post-Translational Modifications
PTMs such as glycosylation also go awry in cancer cells.
This is seen as a result of the initial oncogenic transfor-
mation and a key event in the induction of invasion and
metastasis in cancer [18]. By treating PTMs of proteins
as a separate functional attribute in the Boolean logic,
we found a total of 158 genes whose protein product
harbors at least one PTM. A total of 32 entries with a
PTM were tissue-specific with four overlapping the
kinase set and 64 being secreted proteins, some of
which had already been described in the previous sec-
tions. REG3A, a secreted protein that undergoes a pro-
teolytic cleavage (a form of PTM) is up-regulated in
adenomas, and could be a potential biomarker for the
early detection of colorectal cancer.
DNA methylation as an epigenetic modification
DNA methylation (DNAm) patterns are altered in cancer
cells, as shown by the hypomethylation of oncogenes and
hypermethylation of tumor suppressor genes resulting in
Table 2 The top candidates identified by the GBA algorithm (genes with similar functional attributes are clustered
together)
Candidate
Genes
Normal Adenoma Carcinoma Inflammation Condition
Specificity
Colon
tissue
specificity
Secreted
Proteins
Transcription
Factors
Protein
kinases
PTMs DNA
Methylation
GUCA2B 11.01 5.66 7.52 8.05 ✓ ✓ ✓ ✓
MMP1 6.35 9.2 10.28 10.48 ✓ ✓ ✓
PAPPA 6.51 5.88 7.71 7.12 ✓ ✓ ✓ ✓ ✓
PYY 10.14 4.76 6.87 8.21 ✓ ✓ ✓ ✓ ✓
REG1A 5.71 10.87 10.8 12.17 ✓ ✓ ✓ ✓
MEF2C 8.66 7.36 8.43 9.04 ✓
SOX2 4.18 3.39 4.61 3.89 ✓ ✓ ✓
SPIB 9.11 6.15 6.76 8.26 ✓ ✓ ✓ ✓
WWTR1 8.31 7.22 8.69 8.78 ✓ ✓ ✓
ZIC2 2.22 4.8 3.53 2.55 ✓ ✓ ✓
CDK8 8.62 8.75 8.96 8.29 ✓ ✓
EPHB3 8.58 9.97 8.63 8.12 ✓ ✓ ✓ ✓
ROR2 5.16 4.4 5.47 5.56 ✓ ✓
NPR1 5.02 3.36 4.42 4.71 ✓ ✓ ✓
TRIB3 6.93 8.76 9.01 7.84 ✓
TRPM6 10.54 6.27 8.04 7.08 ✓ ✓ ✓
GCG 10.42 6.24 7.69 9.55 ✓ ✓ ✓ ✓
REG3A 4.95 10.34 10.1 11.19 ✓ ✓ ✓ ✓
SERPING1 8.9 8.11 9.28 10.21 ✓ ✓
SLC4A4 11.76 8.76 9.57 9.81 ✓ ✓ ✓
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gene silencing and gene inactivation respectively [27,28].
Using genome-wide DNA methylome data for colon, we
obtained 99 genes from the GBA algorithm as methylated
genes. 17 of these genes have a preference for colon tis-
sue expression and 19 of them were transcription factors,
23 proteins with a PTM and 22 secreted proteins. The
ADAMTS16, GUCA2B, PYY and THBS2 genes were
hypomethylated, whereas FXYD1 and WWTR1 were
hypermethylated [29]. DNAm information can serve as
additional evidence for these genes as potential candidate
genes and should be further investigated.
Gene co-expression networks reveal novel associations
between cancer and candidate genes
It is thought that co-expressed genes are co-regulated by
similar regulatory mechanisms; hence, possible functional
collaborations between co-expressed genes have been
proposed. To obtain a holistic view of the relationship
between known and novel genes identified by the GBA
algorithm, we constructed a series of gene co-expression
networks using highly correlated differentially expressed
and condition specific genes. Each network contained
1347 genes including the 530 cancer-associated genes
and the 817 candidate genes that were captured by at
least one of the seven expression-based variables (differ-
entially expression or condition specificity). Of the 1 617
503 correlations evaluated in each network, the propor-
tion found to be significant (referred to as clustering
coefficient) according to PCIT algorithm and varied from
4.6% for the Adenoma network to 11.7% for the Carci-
noma network (Table 3). The nodes (genes) and edges
(connections) which were conserved in three or more
network were retained to build what we referred to as
the ‘always-conserved network’.
The always-conserved network shown in Figure 5 was
further dissected into eight different networks and inves-
tigated for their properties. The first four networks were
built in such a way that all the functional attributes were
included. In essence, the first network (Figure 5A) repre-
sents pairs of genes connected in (i) all four networks, (ii)
all four networks except Normal or (iii) all four networks
except Carcinoma. The second network (Figure 5B)
retains only those connections involving at least one top
candidate gene. In the third network (Figure 5C), connec-
tions involving at least one top candidate gene where
both genes have more than two connections are retained.
Finally, the fourth network (Figure 5D) contains the least
number of nodes among those connections involving at
least one top candidate gene with a significant connec-
tion in all the four networks. The remaining four net-
works were constructed based on similar functional
attributes. For instance, the TF-TF only (nodes: 49,
edges: 37) network was built, in which only those con-
nections where a transcription factor is connected to
another transcription factor are retained. Similarly, other
networks based on the post-translational modifications
(nodes: 216, edges: 372), secreted proteins (nodes: 135,
edges: 346) and kinases (nodes: 7, edges: 4) were built.
The always-conserved networks are scale-free networks
and the connectivity of the network follows a power-law
distribution (Additional File 1 Figure S1). We addressed
four key questions in the network analysis section:
(i) which of the top candidate genes are hub genes?
(ii) are there novel functional links between cancer and
non-cancer-associated genes? (iii) are there any highly
connected gene modules functionally relevant to cancer?
and (iv) what is the nature of the attribute networks
(TF-TF, SEC-SEC etc)?
Our network analysis identified a number of hub
genes including several top candidate genes (Figure 5D).
A notable, high impact module with GUCA2B as a hub
gene with 41 connections is significant (Figure 5A).
GUCA2B was connected to other top candidates such as
GUCA2A, CHGA and importantly the nuclear receptor
NR3C2, which is highly implicated in leukemia [30], col-
orectal carcinoma [31], and other carcinomas. Interest-
ingly, CHGA was found to be the central link between
two modules, one with GUCA2B as a hub and another
module where PYY, GCG and CHGB, all candidate
genes, were connected. Because these connections are
based on significant correlations between gene pairs,
they provide the first insights towards functional colla-
borations among the candidate genes found in this
study. A number of network relationships were found
among cancer-associated and non-cancer-associated
genes. The MMP2 gene product which promotes tumor
progression and metastasis by the degradation of the
extra-cellular matrix [32] was connected to genes encod-
ing candidate secreted proteins, C1 S and COL5A1.
We further explored functional relationships between
cancer-associated and non-cancer associated genes by con-
ducting enrichment analysis of GO categories using the
BiNGO plug-in [33]. Among the top ten over-represented
GO terms were anatomical structure development,
immune response, response to stress and negative regula-
tion of biological process. Notably, over-representation of
GO category of importance from the colorectal cancer
Table 3 The properties of network connectivity
Normal Adenoma Carcinoma Inflammation
Normal 5.18 2.28 3.31 4.25
Adenoma 1.20 4.63 8.26 5.25
Carcinoma 2.01 3.89 11.67 11.07
Inflammation 2.30 1.96 4.01 11.10
Clustering coefficients (%, on diagonals) and percent overlap computed from
the ratio of common links divided by the total number of unique links for
positive (above diagonal) and negative (below diagonal) links across each
pair-wise network comparison.
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viewpoint is the inflammatory response, as chronic inflam-
mation is widely believed to be a predisposing factor for
colorectal cancer particularly in individuals with inflamma-
tory bowel diseases; however the underlying molecular
links between these two conditions have remained elusive.
The only documented example is the role of STAT3 that
links inflammation to tumor development in colorectal
cancer [34]. Therefore, our list of candidate genes (C1 S,
CXCL11, and REG3A) where inflammatory response is
over-represented can be considered as potential candidates
for elucidating unresolved cellular mechanisms mediating
this relationship in colorectal cancer.
Next, we applied a combination of the BiNGO and
MCODE plug-ins to study over-represented GO cate-
gories in the sub-networks [35]. Overall, we found 23
sub-networks of which the scores of five sub-networks
were significant (Additional File 1). The first sub-
network comprised of 44 highly connected nodes and 78
edges (4 cancer-associated genes and 40 non-cancer asso-
ciated genes). This cluster was over-represented by GO
terms, phosphate transport and response to external sti-
mulus (that includes candidate genes FPR2 and S100A8).
The cluster also contains several collagen sub-unit genes
(COL4A1, COL3A1, COL1A2, and COL5A2). Again,
over-representation of cell adhesion was evident in the
second cluster with membership from five cancer-asso-
ciated genes including MMP2. These cell adhesion mole-
cules bind to components of the extracellular matrix and
up-regulation and down-regulation of candidate genes
identified in this study may play a role in cancer invasion
and metastasis by altering the ability of cells to adhere to
surrounding cells and the extracellular matrix [36].
Figure 5 The Always Conserved network visualized using the Cytoscape software at our levels of resolution: (A) Connections involving
at least one top candidate gene; (B) derived from A where only genes with more than two connections are displayed; (C) derived from B where
only connections that were deemed to be significant across the four original networks (Adenoma, Carcinoma, Inflammation and Normal) are
displayed; and (D) only those connections involving at least one top candidate gene in the four networks. The specific nature of edges, nodes
and other features such as shape and color along with the Cytoscape file is provided in our website http://www.livestockgenomics.csiro.au/
courses/crc.html.
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Finally, network analysis of similar functional attributes
such as the transcription factors only network and the
secreted proteins only network captured additional regula-
tory hot spots and secreted protein modules that were not
predicted with significant scores previously (Additional File
5). These four networks are of great relevance, since they
are correlated by similar expression patterns, have interre-
lated functional attributes and are candidate non-cancer
associated genes. For instance, in the TF-TF network
(Additional File 5 Figure S1C), the hub genes (NR5A2,
MEF2C) could be seen as regulatory hot spots that control
gene expression via regulation of transcription.
The RIF (Regulatory Impact Factor) analysis
We have recently introduced a novel metric called RIF or
‘regulatory impact factors’ to measure the regulatory
capacity of transcription factors from gene expression
data alone [37]. RIF uses two different measures, RIF1
and RIF2, to predict key regulators (TF) in driving the
phenotypically relevant component of a given co-expres-
sion network. The highest impact regulators (extreme
RIF |z-score| > 2) resulting from the RIF1 and RIF2 ana-
lysis are documented in Additional File 1 Table S3. A few
notable regulators with extreme scores include SAP18,
CDK8, NR3C1, NFYC, CEBPB, PHF19 and TEAD4. Of
particular interest was the accurate prediction of CDK8
as the second-most significant regulator, recently identi-
fied as a colorectal cancer oncogene that regulates beta-
catenin activity [38]. Second, CEBPB was established as a
target gene for regulation in myeloid cells transformed by
the BCR/ABL oncogene and also has a suggested role in
promoting tumor invasiveness. Other potential regulators
predicted by RIF such as EPC1, SAP18 and ZNHIT3 have
no previous link with cancer and therefore provide an
opportunity for further investigation.
Conclusions
The method introduced here is highly flexible and can
be implemented for any cancer type in a rather
straightforward manner. Tissue specificity is one of the
variables in the Boolean combinatorial logic that will
require updating with every cancer type. For instance,
one could study breast or pancreas-specific genes and
their association with cancer by applying this method.
Nuclear receptors are considered to be ideal drug can-
didates for treating breast cancer. We also believe that
this approach could be applied to study other heredi-
tary diseases such as Alzeimer’s and Down’s syndrome,
provided sufficient molecular attributes are available
for the respective diseases. Importantly, the candidate
genes described here are classified based on individual
attributes. Hence, those genes that share a number of
attributes could be ranked as more promising candi-
dates than their counterparts. For instance, PYY is
a differentially expressed, condition-specific, tissue-specific
to the colon, encoded product is a secreted protein that
harbors a PTM and the gene is DNA hypomethylated in
a colon cancer cell line. Therefore, PYY could be consid-
ered as a ‘master candidate’ awaiting further biochemical
characterization. Finally, we argue that this is a holistic
approach that faithfully mimics cancer characteristics,
systematically predicts plausible cancer-associated candi-
date genes and has universal applicability to the study
and advancement of cancer research.
Methods
Gene expression data: Identification of differentially
expressed and condition-specific genes
We used the gene expression data from the colorectal
cancer study of Galamb et al. (2008) profiling the gene
expression from tissue samples classified as one of the
following four conditions: normal (n = 8 samples), ade-
noma (15), carcinoma (15) and inflammation (15). Using
the MAS5 detection call utility, probes yielding an absent
signal in all 53 hybridizations were removed. As a result,
we retained a total of 2 897 775 expression intensity sig-
nals across 34 844 probes that were annotated to 21 892
unique human genes were available for further analysis.
For the identification of differentially expressed genes we
explored three contrasts: 1. Carcinoma vs. Normal; 2. Car-
cinoma vs. Adenoma; and 3. Carcinoma vs. Inflammation.
For each contrast and following previously described
approaches [39], a combination of ANOVA models and
mixtures of distributions were employed to normalize
expression signals and to identify differentially expressed
genes, respectively. In brief, for each of the four datasets,
data normalization was achieved by fitting a parsimonious
mixed-effect ANOVA model containing the main fixed
effect of the hybridization and the random effects of gene,
gene × experimental condition interaction, and residual
error. After building and solving the ANOVA model, the
difference between the normalized expression of a gene in
the two conditions of the given contrast was computed as
the measure of (possible) differential expression. Finally,
differentially expressed genes were identified using a two-
component normal mixture model with an estimated
experiment-wise false discovery rate (FDR) of < 1%.
For the identification of condition specific genes, a
measure of the condition specificity of each gene was
obtained from the ratio of its expression in the j-th con-
dition (j = 1 to 4 for normal, adenoma, carcinoma and
inflammation) over its expression summed across all
four conditions as follows:
CS
x
x
ij
ij
ij
j
=
=
∑
1
4
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Following the above expression, four measures of con-
dition specificity were computed for each gene, and a
gene was set to be condition-specific for the j-th condi-
tion if its expression in the j-th condition was (1) above
the average expression of all genes in the j-th condition;
(2) greater than its expression in any of the other three
conditions; and (3) such that CSij was greater than three
standard deviations of all other CSij’s.
Cancer-associated genes
We compiled a list of cancer-associated genes by man-
ual curation of literature and web-based resources.
More than 1% of all human genes are implicated in
cancer via mutations, and these genes collectively form
the basis of cancer biology [15]. These genes form the
basis of our “cancer-associated genes” dataset. First, we
obtained 437 representative cancer-associated genes
from the Cancer Gene Census at the Sanger Centre
http://www.sanger.ac.uk/genetics/CGP/Census/. Next,
we retrieved a second list of cancer related genes from
the Atlas of Genetics and Cytogenetics in Oncology
[40]. A third list was collated from the disease associa-
tion data of HPRD database [41] and based on high
confidence protein expression entries in multiple cancer
tissues. In addition, we surveyed the lists of genes
reported in the following research and review articles:
[15]; [42]; [43]; and [44]. Finally, we collated these data-
sets to a master list of 749 cancer-associated genes
Additional File 2.
Functional attributes
We retrieved expression data from massively parallel
signature sequencing (MPSS) covering 182 719 tag sig-
natures across 32 tissues [45]. The complete list of TFs
was retrieved from BiblioSphere [46] in the Genomatix
web site http://genomatix.de. The post-translational
modification (PTM) data were downloaded from the
most recent version of the Human Protein Reference
Database (HPRD - Release 9). A list of 1 764 high-
confidence secreted proteins was obtained from the
secreted protein database [47]. A catalogue of 518 pro-
tein kinase genes was downloaded from [48,49]. A list of
alterations in DNA methylation specific for colorectal
cancer using DNAm was obtained from the human
colon cancer methylome [29]. Datasets for functional
attributes are provided in Additional File 2.
The Boolean Logic and the Guilt-by-Association Algorithm
As detailed in Mukherjee et al. [10], a k-ary Boolean
function is a function f: {0,1}k {0,1} which maps each of
the 2k possible states of its binary arguments X = (X1 ...
Xk) to a binary state Y. Such a function can also be
represented as a truth table. In our case, we considered
a total of k = 13 variables in the Boolean logic: Three
measures of differentially expression, four measures of
condition specificity, and the six functional attributes
(TS, TF, PTM, KIN, SEC, and MET). These were binar-
ized (prototypically 0 and 1) and used to compute what
it’s known as the probabilistic truth table, where the
probabilities were obtained from the proportion of
cancer-associated genes presenting a particular profile of
0’s and 1’s across the 13 variables. Therefore, the prob-
abilistic Boolean truth table assigns a probability value
to each existing combination of Boolean variables. In
our case, this probability was derived from the propor-
tion of cancer-associated genes exhibiting that combina-
tion. This trained model was then used as a GBA
algorithm applied to non-cancer related genes in the
human genome.
The GBA algorithm proceeded as follows:
• The particular combination across the 13 Boolean
variables observed for a given non-cancer gene of
interest was decomposed into its roots.
• The probability associated with each root was cap-
tured from the probabilistic Boolean truth table.
• These probabilities were added to rank the impor-
tance of the non-cancer gene of interest as a novel
candidate. We illustrate this concept with an
example.
Let’s consider a gene, MEF2C, being differentially
expressed for the second contrast, TF, PTM and MET.
Across the 13 variables, this is equivalent to the Boolean
profile"0100000011001” which can be decomposed in
the following 14 roots each associated with a probability
value corresponding to the probabilistic Boolean truth
table (Table 4). Probability values on the third column
Table 4 The Boolean probabilistic truth table for MEF2C
gene
No Binarized Boolean profile Probability values
1 0000000000001 0.05094
2 0000000001000 0.23019
3 0000000001001 0.02453
4 0000000010000 0.10755
5 0000000010001 0.03396
6 0000000011000 0.07925
7 0000000011001 0.03019
8 0100000000000 0.01509
9 0100000000001 0.00377
10 0100000001000 0.00377
11 0100000001001 0.00189
12 0100000010000 0.00377
13 0100000010001 0.00189
14 0100000011000 0.00189
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add to 0.58868 and this value is the Boolean score used
in the ranking of MEF2C as a novel cancer-related gene.
Computational Validation of the analytical approach
We designed a two-step approach to ascertain the infer-
ential validity of the proposed GBA. In the first step, we
processed all genes through the Boolean logic using the
previously developed probabilistic truth table and
recorded how extreme the cancer genes were ranked
relative to the other genes. The ratio of the average
Boolean score given to cancer genes over the average
score given to the other genes was used as the threshold
to be applied for the calibration in the second step of
the validation.
The second step of the validation consisted of a standard
cross-validation schema by which a random 4/5 of the
cancer genes comprised the training sample used to build
the GBA to be tested against the remaining 1/5 of the
cancer genes (testing sample). We repeated this process
1000 times, each with a different 4/5 training/1/5 testing
random samples. In each iteration, the number of cancer
genes captured in the top x-percentile (for x = 1,2....,100)
was recorded and used as the measure of sampling distri-
bution upon which to infer the size of the ranked list of
candidate genes that guarantees the threshold obtained in
the step one of the validation is met.
Reconstruction of Gene Co-Expression Networks
The PCIT algorithm [50] was used to reverse-engineer
four gene networks, one for each condition: Normal,
Adenoma, Carcinoma and Inflammation. The networks
were constructed in such a way that a gene pair was
allowed in the network only if it was conserved in at
least three out of four conditions. Therefore, we refer
to these networks as the ‘Always conserved networks’
A network for each of the four conditions, Normal,
Adenoma, Carcinoma and Inflammation, was con-
structed and integrated (intersect) to create four levels
of resolution. The first network (1255 nodes, 5122
edges) was built to include the pairwise connections of
the genes that were connected in all four networks. It
addition, we also produced pair-wise connections of all
genes except the Normal and Carcinoma genes, which
enabled us to investigate exclusive interactions in Nor-
mal and Carcinoma sets. The second network (534
nodes, 5122 edges) retained only those connections
involving at least one top candidate gene. The third
network consisted of those connections involving at
least one top candidate gene and where both genes
had more than two connections (146 nodes, 367
edges). Finally, the fourth network contained those
connections involving at least one top candidate gene
found to be significant in the four networks (99 nodes,
79 edges). The remaining four networks were specific
to the functional attributes. They were the transcrip-
tion factors only, the secreted proteins only and so on
where all of the nodes belonged to one functional
attribute. Functional enrichment using GO was carried
out using BiNGO plug-in [33] in Cytoscape. In this
study, hypergeometric test was used to assess the sta-
tistical significance (p < 0.05) and the Benjamini &
Hochberg False Discovery Rate (FDR) correction.
Identification of key transcription factors
Once the gene networks were obtained we applied the
regulatory impact factor (RIF) algorithm of [37] to iden-
tity the key regulators, with emphasis in those not pre-
viously described as related to cancer. RIF assigns an
extreme score to those transcription factors that are
consistently most differentially co-expressed with the
highly abundant and highly differentially expressed
genes (case of RIF1 score), and to those transcription
factors with the most altered ability to predict the abun-
dance of differentially expressed genes (case of RIF2
score).
Additional material
Additional file 1: Additional text, tables and figures that describe
the rationale behind choosing the functional gene attributes,
cancer pathway analysis and gene co-expression network analysis.
The file contains additional text on rationale behind choosing the
functional gene attributes, text on cancer pathway analysis, figures and
tables on network connectivity and network analysis using MCODE,
BINGO plug-ins and RIF analysis.
Additional file 2: The list of cancer associated genes and publicly
available datasets on functional attributes used in this study. The
list includes cancer associated genes, kinases, transcription factors,
secreted proteins, proteins that undergo post-translational modifications
and genes with CpG island methylation.
Additional file 3: Probabilistic Boolean truth table. The truth table
constructed from 749 cancer associated genes.
Additional file 4: The list of genes ranked by guilt-by-association
algorithm. The list comprises of 138 ranked list of candidate genes.
Additional file 5: Additional network analysis figures. Network
analysis of similar functional attributes (the TF only network, the SEC only
network, TF only network and PTM only network).
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